01 — At a Glance
The Comeback Nobody Believed In
- 52-Week High / Low₹1,610 / ₹610
- Q3 FY26 Revenue₹131 Cr
- Q3 FY26 PAT₹15.2 Cr
- TTM EPS₹14.01
- Annualised EPS (Q1-Q3 Avg × 4)₹18.08
- Book Value / Share₹322
- Price to Book3.50x
- ROCE1.20%
- ROE0.78%
- Sales Growth (TTM)+29%
Flash Summary: Tatva Chintan just posted Q3 FY26 revenue of ₹131 crore, up 52.9% YoY. Profit jumped 10,736% (from ₹0.06 crore loss year ago to ₹15.2 crore profit). The stock is down 17.7% in three months because investors still don’t believe the recovery is real. But management just detailed how a new manufacturing plant goes live next month (Dahej), how another ₹250 crore greenfield breaks ground next (Jolva), and how Euro 7 emissions are about to become the structural tailwind everyone ignored. TL;DR: The company isn’t dead. The market just moved faster than the reality.
02 — Introduction
The Specialty Chemical That Went From ₹45 Cr to ₹6 Cr PAT. And Then… Nobody Watched It Come Back.
Let’s rewind to March 2023. Tatva Chintan reported PAT of ₹45 crore. It was the hero stock. Then China said “nahin bhai, we’re using LNG trucks now,” and stopped buying Structure Directing Agents (SDA) — Tatva’s crown jewel product. Revenue fell. Margins collapsed. By March 2025, PAT was ₹6 crore. The stock got cut in half. CRISIL downgraded the credit ratings. And the market basically wrote this company off as “yet another Indian chemical company that got geopolitically destroyed.”
Then Q3 FY26 happened. Revenue grew 52.9% YoY. EBITDA margin was 19.5% (up from 8% in Q3 FY25). Management went on a concall and explained exactly why this turnaround was structural, not temporary. And the market… did nothing. The stock stayed down because investors were still processing the trauma of 2023-2025.
This is the kind of moment that separates the investors who do homework from those who just check IndiaBulls headlines.
03 — Business Model: WTF Do They Even Make?
Specialty Chemicals For People You Never Heard Of. For Industries You Never Think About.
Members get full access to every article.
